IMS Company Profiles - Report Buyer

IMS COM PANY PRO FILES NOVARTIS SUBSIDIARY LISTING
Tur key (100%); Ciba Vi sion, UK (100%); NeuTec,
UK; Novartis Con sumer Health, UK (100%);
Novartis Pharmaceuticals, UK (100%); Sandoz,
UK (100%); SkyePharma, UK (2%); Vericore, UK
(100%); Alcon, USA (25%); Ciba Vi sion, USA
(100%); Eon Labs, USA (100%); Idenix, USA
(56%); Lek, USA (100%); Novartis Con sumer
Health, USA (100%); Novartis Pharmaceuticals,
USA (100%); Novartis Vaccines, USA (100%);
Protez, USA (100%) (acquired 2008); Sandoz,
USA (100%); Novartis, Venezuela (100%).
NOVARTIS CON SUMER HEALTH
Full Name: Novartis Con sumer Health Schweiz
AG
Postal Ad dress: Postfach, CH-3001 Bern
Street Ad dress: Monbijoustrasse 118, CH-3007
Bern
Tel: +41 31 377 61 11
Fax: +41 31 377 61 00
Email: info@novartis-con sumer-health.ch
Home Page: www.con sumer-health.ch
De scrip tion: Dis trib u tor, pro moter,
sales/detailer. Prod uct ranges in clude: phar ma -
ceu ti cal prod ucts (branded, non-pre scrip tion),
herbal prod ucts. Es tab lished 1998. 114 phar ma -
ceu ti cal em ploy ees in 2007. Di vi sions in clude:
OTC; Medical Nutrition.
Rep re sen ta tives/De tail ers (Pharm, Num -
ber): 30 (2007)
Con tacts (Pharm): Chair man: Mick Clay ton;
Com mer cial Op er a tions: Dominique Giulini; Man -
u fac ture: Adil Naamar; Mar ket Re search:
Benjamin Brechbuhler; Re search & De vel op ment:
Markus Unkauf; Gen eral Con tact: Mick Clayton
Sub sid iary of: Novartis, Swit zer land (100%)
Phar ma ceu ti cal Sales: US$ 75-80 mil lion
Prod ucts (% of Sales by Lead ing 5): 30-35%
Ther a peu tic Classes (% of Sales by Lead ing
5): 50-55%
Dose Forms (% of Sales by Lead ing 5):
75-80%
Prin ci pal Prod ucts:
NEO CITRAN (cold prep a ra tion with out anti-in fec -
tive)
MEBUCAINE F (throat prep a ra tion)
VOLTAREN EMULGEL (antirheumatic top i cal)
FENISTIL (antipruritic; an ti his ta mine sys temic)
OTRIVIN (na sal prep a ra tion top i cal)
Ther a peu tic Range:
cough and cold prep a ra tions 17%
na sal prep a ra tions 11%
throat prep a ra tions 9%
an al ge sics 9%
anti rheu ma tics top i cal 8%
Lead ing Dose Forms:
liq uids 24%
gels/sols 16%
pow ders/gran ules 13%
spe cial solid forms 13%
tab lets 11%
NOVARTIS PHARMACEUTICALS
Full Name: Novartis Pharma Schweiz AG
Postal Ad dress: Postfach, CH-3001 Bern
Street Ad dress: Monbijoustrasse 118, CH-3001
Bern
Tel: +41 31 377 51 11
Fax: +41 31 377 52 11
Home Page: www.novartispharma.ch
De scrip tion: De vel oper, dis trib u tor, pro moter,
sales/detailer. Dis trib utes for other com pa nies.
Prod uct ranges in clude: phar ma ceu ti cal prod ucts
(branded, pre scrip tion), hos pi tal
pharmaceuticals, bio tech nol ogy prod ucts. Es tab -
lished 1997. 240 phar ma ceu ti cal employees in
2005.
Rep re sen ta tives/De tail ers (Pharm, Num -
ber): 51-100 (2005)
Con tacts (Pharm): Chair man: Theodor Sproll;
Gen eral Con tact: Federica Castellano
Sub sid iary of: Novartis, Swit zer land (100%)
Phar ma ceu ti cal Sales: US$ 230-240 mil lion
Prod ucts (% of Sales by Lead ing 5): 40-45%
Ther a peu tic Classes (% of Sales by Lead ing
5): 55-60%
Dose Forms (% of Sales by Lead ing 5):
85-90%
Prin ci pal Prod ucts:
LUCENTIS (oc u lar antineovascularization prod -
uct)
GLIVEC (antineoplastic other)
CO DIOVAN (an gio ten sin-II an tag o nist com bi na -
tion)
ZOMETA (bone cal cium reg u la tor)
SANDIMMUN NEORAL (immunosuppressive
agent)
Ther a peu tic Range:
renin-an gio ten sin sys tem agents 18%
ophthalmologicals 17%
antineoplastics 10%
immunosuppressive agents 8%
musculoskeletal drugs other 7%
Lead ing Dose Forms:
© 2009 IMS Health In cor po rated or its af fil i ates Page 213